Magnesium Hydroxide

Summary

Magnesium Hydroxide (CHEMBL1200718) is an approved small-molecule antacid (ATC G04BX01); indicated across 2 conditions including constipation disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04BX01 (+1 more)
• Indications: 2 conditions
• Clinical trials: 9
• Chemistry: 58.32 Da · H2MgO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200718
Name	Magnesium Hydroxide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	73981
ChEBI	CHEBI:6637
ATC	G04BX01, A02AA04
Molecular formula	H2MgO2
Molecular weight	58.32
InChIKey	VTHJTEIRLNZDEV-UHFFFAOYSA-L

SMILES: [OH-].[OH-].[Mg+2]

IUPAC name: magnesium dihydroxide

ChEBI definition: A magnesium hydroxide in which the magnesium atom is bound to two hydroxide groups.

Pharmacological roles (ChEBI): antacid, flame retardant.

Also known as: Cremaffin, Crm of magnesia, E-528, E528, Hydro-magna, INS NO.528, INS-528, Magnesia, [milk of], Magnesii hydroxidum, Magnesium (as hydroxide), Magnesium hydroxide

Patent coverage: 131,983 distinct patent families (340,030 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	4	MONDO:0002203	MONDO:0002203

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE4	2
PHASE1	2
Not specified	2
PHASE3	1
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05216328	PHASE4	RECRUITING	Prevention of Opioid-induced Constipation in Patients With Advanced Cancer
NCT01773096	PHASE4	COMPLETED	Methylnaltrexone Use for Opioid-induced Postoperative Constipation
NCT01336530	PHASE3	TERMINATED	Tepilta® Versus Oxetacaine, Antacids and Placebo
NCT04802785	PHASE2/PHASE3	UNKNOWN	The Impact of Air Travel on Passenger Cognitive Functions
NCT01037452	PHASE2	COMPLETED	Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn
NCT04269356	PHASE1	COMPLETED	Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants
NCT05109390	PHASE1	COMPLETED	A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults
NCT07235878	Not specified	RECRUITING	12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being
NCT04930237	Not specified	WITHDRAWN	RELISTOR’s Effects on Opioid-Induced Constipation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).